Alimera Sciences resubmits new drug application
Alimera Sciences has resubmitted a new drug application for fluocinolone acetonide implants to address a complete response letter from the US Food and Drug Administration, the company announced in a press release.
Forest Laboratories has agreed a deal with Blue Ash Therapeutics to acquire global rights to a novel antiarrhythmic agent called azimilide.